SCHEMBL4828101

SCHEMBL4828101

O=C(O)c1c[nH]c2ncc(Br)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.54
JAK2 O60674 2/20 0.54
PRKD3 O94806 2/20 0.54
MAP4K4 O95819 2/20 0.54
FGFR1 P11362 2/20 0.54
FLT1 P17948 2/20 0.54
KDR P35968 2/20 0.54
CLK2 P49760 2/20 0.54
CDK5 Q00535 2/20 0.54
MAP4K2 Q12851 2/20 0.54
DYRK1A Q13627 2/20 0.54
TAOK1 Q7L7X3 2/20 0.54
AURKB Q96GD4 2/20 0.54
CLK4 Q9HAZ1 2/20 0.54
PLK4 O00444 1/20 0.54
ROCK2 O75116 1/20 0.54
PRKCG P05129 1/20 0.54
INSR P06213 1/20 0.54
CDK1 P06493 1/20 0.54
FES P07332 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10131672 0.91 CSNK2A1 (0.49) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL28046056 0.90 BRAF (0.53) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL8167329 0.89 AURKA (0.50) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL1516568 0.87 DYRK1A (0.48) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL15882691 0.87 DYRK1A (0.48) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL28512135 0.87 DYRK1A (0.48) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL4831062 0.87 DYRK1A (0.48) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL4831069 0.85 DYRK1A (0.53) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL1516742 0.84 CDK2 (0.46) AURKAJAK2PRKD3MAP4K4FGFR1
SCHEMBL7520159 0.84 AURKA (0.46) AURKAJAK2PRKD3MAP4K4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119241535-A Pyrrolopyridinyl heterocyclic compound, preparation method and application thereof, derivative of pyrrolopyridinyl heterocyclic compound, application of derivative, pharmaceutical composition and application of derivative 济宁医学院附属医院 2025-01-03 CN claimed
CN-108997340-B Synthetic method of 5-bromo-7-azaindole 山东轩德医药科技有限公司 2020-03-20 CN claimed
US-12486264-B2 Bicyclic HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-02 US disclosed
US-12421226-B2 Heteroaryl compounds as necrosis inhibitors, composition and method using the same ACCRO BIOSCIENCE (HK) LIMITED (HK) 2025-09-23 US disclosed
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-07-31 US disclosed
CN-120004785-A Compounds and compositions for the treatment of diseases associated with STING activity 诺华制药股份有限公司 2025-05-16 CN disclosed
EP-3947373-B1 BICYCLIC HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-14 EP disclosed
CN-119241535-A Pyrrolopyridinyl heterocyclic compound, preparation method and application thereof, derivative of pyrrolopyridinyl heterocyclic compound, application of derivative, pharmaceutical composition and application of derivative 济宁医学院附属医院 2025-01-03 CN disclosed
CN-112823036-B Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2024-11-08 CN disclosed
CN-114867718-B Indazole derivatives and use thereof 韩国化学研究院 2024-10-01 CN disclosed
CN-118488947-A Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof 劲方医药科技(上海)有限公司 2024-08-13 CN disclosed
US-20110166175-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-07-07 US disclosed
WO-2010020308-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2010-02-25 WO disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed
WO-2005028475-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421226-B2 Heteroaryl compounds as necrosis inhibitors, composition and method using the same TNF, LITAF, PNLIP AURKA 4005/4885JAK2 1682/4885PRKD3 2384/4885
US-12486264-B2 Bicyclic HPK1 inhibitors PCK1, PGK1, PDXK AURKA 972/4885JAK2 3717/4885PRKD3 163/4885
US-20110166175-A1 7-AZAINDOLE DERIVATIVES JAK3, AZI2, MYLK2 AURKA 884/4885JAK2 16/4885PRKD3 143/4885
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF TRIB2, YAP1, IDO2 AURKA 1305/4885JAK2 2764/4885PRKD3 263/4885
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 AURKA 384/4885JAK2 206/4885PRKD3 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.